Cargando…

Acute liver failure and seizures as a consequence of regorafenib exposure in advanced rectal cancer

BACKGROUND: Regorafenib is a multi-targeted tyrosine kinase inhibitor approved for use in refractory colorectal cancer. We report the first case of seizures secondary to acute liver failure, shortly after initiation of regorafenib in a patient with advanced rectal carcinoma. CASE PRESENTATION: A 64 ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raissouni, Soundouss, Quraishi, Zarqa, Al-ghamdi, Mohammed, Monzon, Jose, Tang, Patricia, Vickers, Michael M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4593199/ https://www.ncbi.nlm.nih.gov/pubmed/26438070 http://dx.doi.org/10.1186/s13104-015-1502-4

Ejemplares similares

Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation
por: Dudani, Shaan, et al.
Publicado: (2019)

Fatal Acute Liver Failure as a Consequence of Regorafenib Treatment in a Metastatic Colon Cancer
por: Béchade, Dominique, et al.
Publicado: (2017)

Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
por: Amram, Marie-Laure, et al.
Publicado: (2017)

Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer
por: Ravi, Sujan, et al.
Publicado: (2014)

Classic Kaposi's sarcoma in morocco: clinico -epidemiological study at the national institute of oncology
por: Errihani, Hassan, et al.
Publicado: (2011)

Immediate-term cognitive impairment following intravenous (IV) chemotherapy: a prospective pre-post design study
por: Khan, Omar F., et al.
Publicado: (2019)

The effect of gastrectomy on regorafenib exposure and progression‐free survival in patients with advanced gastrointestinal stromal tumours
por: Lubberman, Floor J.E., et al.
Publicado: (2019)

The impact of driving time, distance, and socioeconomic factors on outcomes of patients with locally advanced rectal cancer
por: Gotfrit, Joanna, et al.
Publicado: (2020)

Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
por: Kelley, Robin K., et al.
Publicado: (2020)

The Role of Regorafenib in the Management of Advanced Gastrointestinal Stromal Tumors: A Systematic Review
por: Khachatryan, Vahe, et al.
Publicado: (2022)

Spermatocytic seminoma at the National Institute of Oncology in Morocco
por: Raiss, Ghizlane G, et al.
Publicado: (2011)

Spermatocytic seminoma at the national institute of oncology in Morocco
por: Raiss, Ghizlane G, et al.
Publicado: (2011)

The Impact of Chronic Kidney Disease in Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation
por: Dudani, Shaan, et al.
Publicado: (2021)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer
por: Sastre, J., et al.
Publicado: (2014)

Real-Life Experience of Regorafenib in Patients With Advanced Hepatocellular Carcinoma
por: Hou, Jing-Yu, et al.
Publicado: (2022)

Efficacy of regorafenib in acute pulmonary carcinomatous lymphangitis as a manifestation of rectal cancer: A case report
por: Takeuchi, Nobumichi, et al.
Publicado: (2019)

Regorafenib-Induced Radiation Recall Presenting as Acute Blood Loss Anemia With Rectal Bleeding and Severe Proctitis
por: Urella, Madhulika, et al.
Publicado: (2023)

Radiation induced esophageal adenocarcinoma in a woman previously treated for breast cancer and renal cell carcinoma
por: Raissouni, Soundouss, et al.
Publicado: (2012)

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment: A meta-analysis
por: Zhang, Zhenan, et al.
Publicado: (2017)

Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study
por: Huang, Jingjun, et al.
Publicado: (2022)

The success of regorafenib in hepatocellular carcinoma in a world of failures. Learnings for future developments
por: Reig, Maria, et al.
Publicado: (2017)

Erythema multiforme induced by regorafenib
por: Matsunaga, Mototsugu, et al.
Publicado: (2017)

Successful Sequential Therapy Involving Regorafenib after Failure of Sorafenib in a Patient with Recurrent Hepatocellular Carcinoma after Liver Transplantation
por: Lee, Soon Kyu, et al.
Publicado: (2020)

Interaction Between Sex and Organic Anion‐Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib‐N‐Oxide and Regorafenib‐Glucuronide in Mice
por: Fu, Qiang, et al.
Publicado: (2019)

Unusual case of cavitary lung metastasis from squamous cell carcinoma of the uterine cervix
por: Raissouni, Soundouss, et al.
Publicado: (2013)

Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature
por: Korphaisarn, Krittiya, et al.
Publicado: (2017)

Benefit‐Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib
por: Pelosof, Lorraine, et al.
Publicado: (2018)

A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies
por: How, Joan, et al.
Publicado: (2022)

Primary pleural leiomyosarcoma with rapid progression and fatal outcome: a case report
por: Rais, Ghizlane, et al.
Publicado: (2012)

Liposarcome dédifférencie du cordon spermatique: difficultés thérapeutiques des grosses tumeurs
por: Rais, Ghizlane, et al.
Publicado: (2011)

Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study
por: Xu, Yongkang, et al.
Publicado: (2023)

Incidence and risk of regorafenib-induced hepatotoxicity
por: Zhao, Bin, et al.
Publicado: (2017)

Experience with regorafenib in the treatment of hepatocellular carcinoma
por: Granito, Alessandro, et al.
Publicado: (2021)

Characterization of Glioblastoma Cells Response to Regorafenib
por: Mongiardi, Maria Patrizia, et al.
Publicado: (2022)

Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: observational monocentric study of about 100 patients
por: Aitelhaj, Meryem, et al.
Publicado: (2013)

Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma
por: Choi, Won‐Mook, et al.
Publicado: (2020)

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
por: Strumberg, D, et al.
Publicado: (2012)

Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocol
por: Hendlisz, Alain, et al.
Publicado: (2015)

A multi-center retrospective study on the efficacy and safety of regorafenib vs. regorafenib combined with PD-1 inhibitors as a second-line therapy in patients with advanced hepatocellular carcinoma
por: Yan, Tao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8me94dv7n0sv30anuk2rqsmvct